Palvella Therapeutics, Inc.
Financials
Valuation Metrics
Palvella Therapeutics, Inc.'s Market Cap is $2.10B. At end of 2025 it was $1.18B. Ranked #1928 of 3,116 in US market (top 62%), #716 of 1,472 on NASDAQ (top 49%), #130 of 265 in Pharmaceuticals, Biotechnology & Life Sciences (top 49%) by Market Cap.
Investment Metrics(as of 2026-10-30)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $2.10B | US#1,928/3,116 Sec#130/265 |
| Revenue | $0.00 | US#2,859/3,116 Sec#193/265 |
| Net Income | $-62M | US—/3,116 Sec—/265 |
| Total Assets | $254M | US#2,936/3,116 Sec#223/265 |
| Net Assets | $217M | US#2,646/3,116 Sec#185/265 |
| Employees | 29 | US#2,735/3,116 Sec#217/265 |
| Value | ||
| P/B | 9.67x | US#2,610/3,116 Sec#192/265 |
| FCF Yield | -1.74% | US—/3,116 Sec—/265 |
| Profitability | ||
| ROE | -28.45% | US#2,549/3,116 Sec#112/265 |
| ROA | -24.34% | US#2,838/3,116 Sec#142/265 |
| Financial Health | ||
| Debt Ratio | 16.87% | US#190/3,116 Sec#70/265 |
| Total Debt | $535000.00 | US#2,983/3,116 Sec#251/265 |
| FCF | $-37M | US#2,482/3,116 Sec#104/265 |
| Cash | $188M | US#1,779/3,116 Sec#113/265 |
| Current Ratio | 21.18x | US#111/3,116 Sec#22/265 |
| Performance | ||
| 1Y Return | 86.37% | US#148/3,116 Sec#36/265 |
| 1M Return | 5.96% | US#824/3,116 Sec#60/265 |
| From 52W High | -9.44% | US#561/3,116 Sec#40/265 |
| 1Y MDD | -31.11% | US#1,391/3,116 Sec#71/265 |
| Trading | ||
| Volume | 276,477 shares | US#2,350/3,116 Sec#225/265 |
| Trading Value | $41M | US#1,289/3,116 Sec#93/265 |
| Per Share | ||
| EPS | $-4.30 | US—/3,116 Sec—/265 |
| BPS | $15.12 | US#1,515/3,116 Sec#47/265 |
Company Info
Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative treatments for patients afflicted with severe and uncommon inherited skin conditions. Central to its pipeline is QTORIN 3.9% rapamycin anhydrous gel (referred to as QTORIN rapamycin), which is currently undergoing Phase 3 clinical trials for microcystic lymphatic malformations. Additionally, this drug is in Phase 2 evaluation for treating cutaneous venous malformations. Beyond these specific indications, Palvella is also advancing QTORIN rapamycin for the treatment of other dermatological diseases driven by the mTOR pathway. The company's headquarters are situated in Wayne, Pennsylvania.